| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 May 2026 | 19 May 2026 |
| Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 inter alia to consider and approve 1. Audited Financial Results for the quarter and year ended 31.03.2026 2. Audit Report for the year ended 31.03.2026 3. Any other item with the permission of chair. Outcome of the Board meeting held on 23rd May, 2026. (As per BSE announcement dated on :23.05.2026) | ||
| Board Meeting | 4 Feb 2026 | 30 Jan 2026 |
| Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 inter alia to consider and approve 1. Un-audited Financial results for the quarter ended December 31 2025. 2. Limited Review Report for the quarter ended December 31 2025. 3. Any other business with the permission of the Chair. With reference to the subject cited, this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited, at its Meeting held on Wednesday, 04th February, 2026, at 12:00 noon at the corporate office of the Company, considered and approved the following: 1. Un-audited Financial Results for the quarter and nine months ended 31.12.2025. (Attached as Annexure) 2. Limited Review Report for the quarter and nine months ended 31.12.2025. (Attached as Annexure) 3. Re-constitution of Internal Complaints Committee (ICC) constituted under The Sexual Harassment of Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013 (POSH Act) w.e.f., 04.02.2026. (Attached as Annexure -I) (As per BSE Announcement dated on: 04.02.2026) | ||
| Board Meeting | 7 Nov 2025 | 3 Nov 2025 |
| Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2025 inter alia to consider and approve 1. Un-audited Financial results for the quarter and half year ended September 30 2025. 2. Limited Review Report for the quarter ended September 30 2025. 3. Any other business with the permission of the Chair. Outcome of the Board meeting held on 07.11.2025 (As Per Bse Announcement dated on 07/11/2025) | ||
| Board Meeting | 25 Aug 2025 | 25 Aug 2025 |
| Outcome of Board meeting held on 25.08.2025. | ||
| Board Meeting | 14 Aug 2025 | 11 Aug 2025 |
| Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve 1. Un-audited Financial results for the quarter ended June 30 2025. 2. Limited Review Report for the quarter ended June 30 2025. 3. Any other business with the permission of the Chair. Outcome of Board Meeting for the Un-audited financial results for quarter ended 30.06.2025 and other matters under Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As Per BSE Announcement Dated on: 14.08.2025) | ||
| Board Meeting | 20 Jun 2025 | 20 Jun 2025 |
| We hereby attaching you the board meeting outcome | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
